Fig. 7.

Epigenetic repression of combined nafamostat mesylate and PAL on CDK4/6 expression in endocrine-resistant estrogen receptor-positive breast cancer cells. (A) Levels of CDK4 and CDK6 expression in combined NM and PAL-treated MCF7-TamR (upper) and MCF7-FulR (lower) cells, assessed using western blot analysis with specific antibodies. (B) mRNA levels of CDK4 and CDK6 in MCF7-TamR (upper) and MCF7-FulR (upper) cells treated with NM and PAL, assessed using quantitative PRC analysis. (C) Levels of Histone 3 modification in MCF7-TamR (upper) and MCF7-FulR (lower) cells treated with NM and PAL, assessed using western blot analysis with specific antibodies. Data are represented as the mean ± SEM for biological triplicate experiments. *P < 0.01, compared with the results for untreated MCF7-FulR and MCF7-TamR cells.